Riccardo et al. tested hCSPG-4 vaccination in dogs with stage II-III oral malignant melanoma and noted extended 6- and 12-month survival times following surgical resection and vaccination compared to animals who received surgery alone, accompanied by an increase in anti-CSPG-4 antibodies in serum [35]. The gene discussed is CSPG4; the disease is melanoma.